🇺🇸 FDA

Company profile · Sponsor

Aprea

Aprea Therapeutics

APRE · NYSE pharma DOYLESTOWN, PA, USA
Pipeline
15
Drugs
0
Patents
6

Quick answer

Aprea (APRE) is a pharma company. headquartered in DOYLESTOWN, PA, USA. listed on NYSE. NovaPharmaNews links 15 pipeline programs, 0 drugs, and 6 patents to this profile..

Company facts

Ticker APRE
Exchange NYSE
Company type pharma
Headquarters DOYLESTOWN, PA, USA
SEC CIK 0001781983

Pipeline (15)

Search pipeline →

  1. APR-246 + azacitidine

    Aprea

    MDS

    phase 3 small molecule completed

    1 trial

  2. APR-246

    Aprea

    Acute Myeloid Leukemia or Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  3. APR-246

    Aprea

    Myelodysplastic Syndrome With Gene Mutation

    phase 2 small molecule active

    1 trial

  4. APR-246

    Aprea

    Melanoma

    phase 2 small molecule terminated

    1 trial

  5. APR-246

    Aprea

    Myelodysplastic Syndrome

    phase 2 small molecule completed

    1 trial

  6. APR-246

    Aprea

    Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

    phase 2 small molecule completed

    1 trial

  7. APR-246

    Aprea

    High-grade Serous Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  8. APR-246 (eprenetapopt) + Acalabrutinib in CLL

    Aprea

    Non Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  9. APR-246 (eprenetapopt) + Pembrolizumab

    Aprea

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  10. ATRN-119

    Aprea

    HPV Positive Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  11. ATRN-119

    Aprea

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  12. APR-1051

    Aprea

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  13. APR-246

    Aprea

    Hematologic Neoplasms

    phase 1 small molecule completed

    1 trial

  14. APR-246

    Aprea

    Myeloid Malignancy

    phase 1 small molecule completed

    1 trial

  15. APR-548 + Azacitidine

    Aprea

    MDS

    phase 1 small molecule terminated

    1 trial

Patents (6)

Search patents →

  1. US 9061016

    Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7902167

    Compounds and methods for down-regulating Wrap53 protein by RNA interference

    Expires Mon Mar 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7759361

    Azabicyclooctan-3-one derivatives and use thereof

    Expires Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7659278

    Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases

    Expires Mon Feb 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7348330

    1-azabicyclo [2,2,2] octan-3-one derivatives

    Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 6921765

    1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors

    Expires Mon Jul 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is Aprea?

Aprea (APRE) is a pharma company. headquartered in DOYLESTOWN, PA, USA. listed on NYSE. NovaPharmaNews links 15 pipeline programs, 0 drugs, and 6 patents to this profile..

What pipeline programs does Aprea sponsor?

We track 15 ClinicalTrials.gov-linked programs for Aprea, including APR-246 + azacitidine and 14 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Aprea company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.